Procept Biorobotics

PRCT

Market cap $1.77B

SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 37th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Tuesday, December 2 at 8:30 a.m. Eastern Time.

The portfolio generated a modestly positive absolute return in Q3, but it trailed the MSCI All Country World Small Mid Index. The Q3 underperformance was driven by stock selection in the IT, financials and consumer discretionary sectors. On the positive side, stock selection in the health care and industrials sectors was the strongest contributor to performance.

PROCEPT BioRobotics Corporation ( PRCT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Matthew Bacso - Vice President of Investor Relations Larry Wood - President, CEO & Director Kevin Waters - Executive VP & CFO Conference Call Participants Matthew O'Brien - Piper Sandler & Co., Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Richard Newitter - Truist Securities, Inc., Research Division Patrick Wood - Morgan Stanley, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Christopher Pasquale - Nephron Research LLC Suraj Kalia - Oppenheimer & Co. Inc., Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Mason Carrico - Stephens Inc., Research Division Joshua Jennings - TD Cowen, Research Division Brett Gasaway - Leerink Partners LLC, Research Division Michael Sarcone - Jefferies LLC, Research Division Stephanie Piazzola - BofA Securities, Research Division Presentation Operator Good afternoon, and welcome to PROCEPT BioRobotics Third Quarter 2025 Earnings Conference Call.

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.4 per share a year ago.

SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2025.

Robotics companies building enabling systems like sensors and LiDAR attracted $1.6 billion in 2025, as every robot needs vision capabilities. Medical robotics shows the clearest path from startup to profitability, with surgical automation growing 56% annually in emerging procedures.

PROCEPT BioRobotics (PRCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chicago Capital added 999,873 shares of Procept BioRobotics with an estimated purchase value of $45.65 million based on the average price for the quarter. The transaction represents a trade size equal to 1.12% of Chicago Capital's 13F reportable assets under management (AUM) for the period.

SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

PROCEPT BioRobotics stands out in BPH therapy with its unique Aquablation technology and razor-and-blade business model, driving strong, recurring growth. PRCT's robust R&D investment, expanding indications, and international momentum support margin expansion, scalability, and long-term growth in its niche market. Valuation is attractive at current levels, with a DCF-derived target price of $50.9 and profitability expected by the end of 2027, offering an attractive accumulation opportunity.